undamentalytics Newsletter
Sign in

ADC Therapeutics SA cash flow statement

In fiscal 2025, ADC Therapeutics SA's operations generated −$141m of cash; it spent $264,000 on capital projects, leaving free cash flow of −$141m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−138−119−124−141−102
Depreciation and amortisation1111—
Stock-based pay49137710
Capital spending13100
Free cash flow−139−122−125−141−102
Free cash flow after stock pay−188−135−131−148−112
Shares issued—0618643

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AAPG vs ADCTADCT vs PLXADCT vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ADC Therapeutics SA's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ADC Therapeutics SA.